Guide to Understanding Cabenuva for Long Acting HIV Care

Cabenuva is a long acting HIV treatment that combines two antiretroviral medicines, cabotegravir and rilpivirine, administered as injections by a healthcare professional. It may provide an alternative to taking daily oral HIV medication for eligible adults whose HIV is already controlled. Understanding how Cabenuva works, its treatment schedule, possible side effects, and the importance of regular medical appointments can help individuals discuss suitable options with their healthcare providers. Treatment decisions should consider medical history, current medications, viral suppression, and the ability to maintain the required injection schedule consistently.

Cabenuva is a prescription treatment used for certain adults living with HIV whose infection is already virologically suppressed on a stable antiretroviral regimen. Unlike traditional daily oral HIV medicines, Cabenuva is administered as long acting injections containing cabotegravir and rilpivirine. This approach may offer an alternative treatment routine for eligible individuals. However, treatment suitability depends on several clinical factors, and regular communication with a healthcare professional remains important throughout therapy.

How Cabenuva Works as a Long Acting HIV Treatment

Cabenuva combines two different antiretroviral medicines that work against HIV in separate ways. Cabotegravir is an integrase strand transfer inhibitor, which interferes with an important step in the HIV replication process. Rilpivirine is a non nucleoside reverse transcriptase inhibitor that affects another stage of viral replication.

The medicines are given as injections into the muscles by a trained healthcare professional according to an approved treatment schedule. Before starting treatment, healthcare providers evaluate whether an individual meets the clinical requirements for this regimen.

Important aspects of Cabenuva treatment include:

• It is intended for eligible adults with HIV whose viral load is already suppressed.
• The treatment combines cabotegravir and rilpivirine in a long acting injectable regimen.
• Injections are administered by a healthcare professional rather than being self injected at home.
• Treatment appointments must be attended according to the prescribed schedule.
• Healthcare providers may review other medications because drug interactions can affect treatment.
• Some individuals may require additional evaluation before switching from their existing HIV treatment.

Long acting treatment does not mean HIV is cured. Antiretroviral therapy helps control viral replication and maintain viral suppression when used appropriately. Continued medical monitoring and treatment adherence remain essential.

Treatment Schedule Safety and Important Considerations

One of the main features of Cabenuva is its extended dosing schedule compared with taking oral medication every day. Depending on the prescribed regimen, injections may be administered at regular monthly or every two month intervals. The appropriate schedule is determined by the healthcare provider based on approved treatment guidance and individual circumstances.

Potential considerations during treatment include:

• Injection site reactions such as pain, swelling, redness, or discomfort may occur.
• Some people may experience symptoms such as headache, tiredness, fever, nausea, or sleep related changes.
• Missing scheduled injections may require medical guidance to maintain appropriate HIV treatment coverage.
• Certain medicines may interact with cabotegravir or rilpivirine.
• Liver health, medical history, and previous HIV treatment may be considered before and during therapy.
• Regular HIV monitoring helps healthcare providers assess continued viral suppression.